Clinical Trials Browser

Phase 2 × Recurrence × STA 9090 × Clear all

NCT01173523 2019-04-16

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer

Phase 2 Completed

25 enrolled 8 charts

Recurrence, Small Cell Lung Carcinoma